Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Susceptibility

Aspergillus fumigatus Clinical Isolates Carrying CYP51A with TR34/L98H/S297T/F495I Substitutions Detected after Four-Year Retrospective Azole Resistance Screening in Brazil

Laís Pontes, Caio Augusto Gualtieri Beraquet, Teppei Arai, Guilherme Leite Pigolli, Luzia Lyra, Akira Watanabe, Maria Luiza Moretti, Angélica Zaninelli Schreiber
Laís Pontes
aSchool of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caio Augusto Gualtieri Beraquet
aSchool of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Teppei Arai
bMedical Mycology Research Center, Chiba University, Chiba, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guilherme Leite Pigolli
aSchool of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Luzia Lyra
aSchool of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Akira Watanabe
bMedical Mycology Research Center, Chiba University, Chiba, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Luiza Moretti
aSchool of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angélica Zaninelli Schreiber
aSchool of Medical Sciences, University of Campinas, Campinas, São Paulo, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Angélica Zaninelli Schreiber
DOI: 10.1128/AAC.02059-19
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

Azole antifungal resistance in Aspergillus fumigatus is a worldwide concern. As in most public hospitals in Brazil, antifungal susceptibility tests are not routinely performed for filamentous fungi at our institution. A 4-year retrospective azole antifungal resistance screening revealed two azole-resistant A. fumigatus clinical isolates carrying the CYP51A TR34 (34-bp tandem repeat)/L98H (change of L to H at position 98)/S297T/F495I resistance mechanism mutations, obtained from two unrelated patients. Broth microdilution antifungal susceptibility testing showed high MICs for itraconazole, posaconazole, and miconazole. Short tandem repeat (STR) typing analysis presented high levels of similarity between these two isolates and clinical isolates with the same mutations reported from the Netherlands, Denmark, and China, as well as environmental isolates from Taiwan. Our findings might indicate that active searching for resistant A. fumigatus is necessary. They also represent a concern considering that our hospital provides tertiary care assistance to immunocompromised patients who may be exposed to resistant environmental isolates. We also serve patients who receive prophylactic antifungal therapy or treatment for invasive fungal infections for years. In these two situations, isolates resistant to the antifungal in use may be selected within the patients themselves. We do not know the potential of this azole-resistant A. fumigatus strain to spread throughout our country. In this scenario, the impact on the epidemiology and use of antifungal drugs will significantly alter patient care, as in other parts of the world. In summary, this finding is an important contribution to alert hospital laboratories conducting routine microbiological testing to perform azole resistance surveillance and antifungal susceptibility tests of A. fumigatus isolates causing infection or colonization in patients at high risk for systemic aspergillosis.

INTRODUCTION

Aspergillus is a genus of fungi comprising over 300 different species distributed worldwide, Aspergillus fumigatus being the most commonly isolated species (1). Aspergillus infections demonstrate a wide variety of clinical manifestations, including allergic bronchopulmonary aspergillosis (ABPA), skin infections that result in cutaneous aspergillosis, aspergilloma, chronic pulmonary aspergillosis, and invasive aspergillosis (IA). Currently, IA is the main cause of morbidity and mortality in immunocompromised patients (2, 3). Although the first-choice antifungals for aspergillosis treatment are azoles, a wide variety of mutations in the CYP51A gene have been reported in azole-resistant isolates; the CYP51A gene encodes the cytochrome P450 14-α-lanosterol demethylase, the main target of azole antifungals (1, 4).

Many studies have reported the existence of resistance attributed to mutations in the CYP51A gene. Strains harboring these substitutions were reported in Europe, Asia, and the United States (5–8). In South America, such findings have already been reported from Colombia (2017), describing TR34 (34-bp tandem repeat)/L98H (change of L to H at position 98), TR46/Y121F/T289A, and TR53 mutations found in environmental isolates, from Argentina (2018), relative to a clinical isolate collected in 2009 carrying TR46/Y121F/T289A mutations, and from Peru (2017), in a clinical isolate carrying TR34/L98H mutations (9–11).

In Brazil, many researchers are studying the azole susceptibility profiles of A. fumigatus strains (12–14), and at present, there is one abstract from ISHAM 20th describing TR34/L98H mutations found in a clinical A. fumigatus isolate and a CYP51A gene point mutation resulting in an M220R mutation obtained from an isolate collected from a crop in southern Brazil (15).

The University of Campinas Clinical Hospital (UNICAMP) (https://www.hc.unicamp.br/node/76) is a reference tertiary hospital for the city of Campinas and a macroregion of 86 municipalities of São Paulo State, with about 6.5 million inhabitants. Also, patients from several other states, such as Minas Gerais, Paraná, Bahia, Rio de Janeiro, and Mato Grosso, are treated on an outpatient basis in almost all specialties and clinical and surgical subspecialties, including rarer and more complex ones. In addition to over 400 beds, more than 10,000 people circulate daily at our institution.

In this hospital, as in most public hospitals in Brazil, antifungal susceptibility tests are not routinely performed for filamentous fungi. A retrospective azole antifungal resistance screening revealed our first two azole-resistant A. fumigatus clinical isolates carrying the CYP51A TR34/L98H/S297T/F495I resistance mechanism mutations.

RESULTS

Azole-resistant A. fumigatus isolates were detected after retrospective azole resistance screening of a selection of 199 isolates maintained at the Laboratory of Fungal Investigation (LIF) collection of the Clinical Pathology Department, School of Medical Sciences, UNICAMP. The isolates were obtained from patients with different underlying diseases for routine microbiological diagnosis from 2014 to 2017. Only 2 isolates (LIF 2444-6 and LIF 2552-4.9) from 2 different patients (which represent 1% of the isolates and 4.5% of the patients) were able to grow at the highest concentration in the screening test for itraconazole and showed high MICs for almost all azoles after performing the broth microdilution antifungal susceptibility test (Table 1). A tandem duplication of a 34-bp sequence (5′-X-3′) was found between positions 163 and 230 of the start codon (Fig. 1A). In addition, sequence analysis of the CYP51A open reading frame (ORF) showed three substitutions, T293A, T889A, and T1483A, that resulted in amino acid changes L98H, S297T, and F495I (Fig. 1B). Short tandem repeat (STR) typing analysis for nine microsatellite markers, 2A, 2B, 2C, 3A, 3B, 3C, 4A, 4B, and 4C (16), showed high levels of similarity between the two isolates and clinical isolates with the same mutations reported from the Netherlands, Denmark, and China, as well as environmental isolates from Taiwan (Fig. 2) (16, 17).

View this table:
  • View inline
  • View popup
  • Download powerpoint
TABLE 1

In vitro antifungal susceptibilities of the 2 A. fumigatus isolates and CYP51A sequencing results

FIG 1
  • Open in new tab
  • Download powerpoint
FIG 1

(A) Nucleotide sequence alignment showing TR34 repeat on isolates LIF 2444-6 and LIF 2552-4.9. (B) Protein sequence alignment.

FIG 2
  • Open in new tab
  • Download powerpoint
FIG 2

Genotypic relationship between LIF 2444-6 and LIF 2552-4.9 and Aspergillus fumigatus isolates with TR34/L98H/S297T/F495I mutations from China, the Netherlands, Denmark, and Taiwan (16, 17). The dendrogram is based on a categorical analysis of nine microsatellite markers in combination with unweighted pair group method with arithmetic mean (UPGMA) clustering using Phyloviz 2.0a.

DISCUSSION

Isolate LIF 2444-6 was obtained from sputum in routine culture controls for cystic fibrosis patients on 28 July 2015, from a 24-year-old male patient with chronic lung disease, followed at the Pulmonology Outpatient Clinic. There is no hospitalization record for him and no data in his folder from 1999 to 2016.

A. fumigatus LIF 2552-4.9 was isolated from sputum in routine microbiological diagnosis culture on 2 December 2015. Clinical data available in the Clinical Laboratory were that the 54-year-old male patient was diabetic with bronchiectasis in the right lung. Samples collected on the same date had negative results in examination for tuberculosis, a positive result in direct examination for Paracoccidioides spp., and after standard incubation time, a positive culture for A. fumigatus.

According to routine laboratory procedures in 2015, identification was based only on macro- and micromorphology, no antifungal susceptibility test was performed, and the isolates were added to the Laboratory of Fungal Investigation (LIF) collection of the Clinical Pathology Department, School of Medical Sciences, University of Campinas.

In this paper, we report two azole-resistant A. fumigatus strains that harbor the CYP51A TR34/L98H/S297T/F495I mutations, detected in our institution after an azole resistance screening test. These mutations have already been described in Denmark, the Netherlands, China (16), and Taiwan (17) and were related to high MICs for itraconazole and imidazoles.

According to Chen et al. (16), it was possible to show that the F495I substitution is related to high MICs to imidazoles. It was possible to evaluate an imidazole (miconazole), which is already included in the commercial plate used (Eiken Chemical Co., Tokyo, Japan), with a MIC of >16 μg/ml, confirming the relationship of high MICs for this antifungal class and the F495I substitution.

According to STR analysis, our isolate, although it seems to be closer to the isolates of Denmark and the Netherlands, has its own pattern. Isolates with this type of mutation were mostly considered environmental. These isolates of A. fumigatus were considered by the attending clinicians as colonizing agents, and the patients received no treatment.

What stands out is the fact that the two microorganisms were isolated in the same year (2015), although 5 months apart. These patients live in different cities, and as neither patient was admitted during this period, the only common space attended by both was the outpatient clinic of the hospital.

As this is a retrospective study, the resistant microorganisms having been detected among the isolates from 2015, a limitation that cannot be solved is to perform related environmental sampling. But surveillance air collection was conducted by our study group in each of the four seasons during the whole of 2015 in two different environments in the hospital: the bone marrow transplant ward (with filtered air) and the hematology ward (with open windows, thus reflecting the air composition around the hospital) (18). Among the 123 Aspergillus isolates found were 62 A. fumigatus isolates, none of which showed resistance to azoles in the azole screening test. After CYP51A gene sequencing, one isolate showed the amino acid exchange N248K derived from a point mutation and 12 isolates showed F46Y, M172V, N248T, D255E, and E427K mutations, found not only in environmental isolates but also in isolates from patients preexposed to azole drugs (19).

Our findings might indicate that resistant A. fumigatus strains from our region may carry these or other mutations. Due to the protocol for collecting a single colony from each distinct morphology in routine diagnostic cultures, we may have missed the opportunity to detect other equally resistant isolates, whether carrying these mutations or not. This represents a concern, especially considering that our hospital provides tertiary care assistance to immunocompromised patients who may be exposed to resistant environmental isolates. Other patients receive prophylactic antifungal agents, and patients with invasive fungal infections receive antifungal therapy for years. In these two situations, isolates resistant to the antifungal in use may be selected within the patients themselves (1).

We do not know the potential of this azole-resistant A. fumigatus strain carrying the CYP51A mutations to spread throughout our country. In this scenario, the impacts on epidemiology and the use of antifungal drugs will significantly alter patient care, as in other parts of the world.

In summary, this description of the CYP51A mutations in our health care area is an important contribution to alert hospital laboratories conducting routine microbiological testing to perform azole resistance surveillance and antifungal susceptibility tests of A. fumigatus strains causing infection or colonization in patients at high risk for systemic aspergillosis.

MATERIALS AND METHODS

Aspergillus fumigatus isolates.One hundred ninety-nine sequential A. fumigatus isolates obtained from different clinical specimens from 44 patients with 2 or more isolates from January 2014 to March 2017 were selected. The age of the patients ranged from 10 to 71 years, considering the date of first isolation. The number of isolates ranged from 2 to 12 per patient, whose main underlying diseases were cystic fibrosis (78%), immunosuppression (9%), tuberculosis (2%), paracoccidioidomycosis (2%), diabetes mellitus (2%), and not available (2%). Only for 9 patients (20%) is there a record of the administration of itraconazole prior to fungal isolation. At the time of preparation of the manuscript, death was recorded for 20% of patients, which does not include the patients with resistant isolates. All isolates were stored in distilled water at room temperature using Castellani’s method (20). The macromorphology and micromorphology of each isolate were observed after pure growth on Sabouraud dextrose agar (SDA) and potato dextrose agar (PDA; Difco, Sparks, MD, USA).

Molecular identification.Genomic DNA was extracted after 48 to 72 h of growth at 25°C on SDA plates using a DNeasy tissue kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions. Comparative DNA analyses of beta-tubulin (β-tubulin 2A/-B) sequences were performed for species confirmation (21). The resultant nucleotide sequences were analyzed using Geneious 8.1 (2015; Biomatters Ltd., Newark, NJ, USA) and compared with external databases.

Azole resistance screening.Mueller-Hinton agar plates (MH) with 2% dextrose were prepared by adding the antifungal dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich, St. Louis, MO, USA) to reach a final concentration of 2 μg/ml for itraconazole and voriconazole and 0.5 μg/ml of posaconazole. (Sigma-Aldrich, St. Louis, MO, USA). After up to 3 days fungal growth at 35°C in PDA slants, inoculums were prepared to final concentrations of 5.5 × 104 to 2 × 105 CFU/ml. Amounts of 20 μl of inoculum suspensions were deposited on the agar plates containing the antifungal agents. For growth controls, the same inoculums were also deposited on plates without the antifungal agents. The tests were read after 48 h of incubation at 35°C.

Broth microdilution.The isolates capable of growth in the screening test were submitted to antifungal susceptibility tests according to the CLSI M38-A2 (22) protocol, using preprepared plates for itraconazole, voriconazole, and miconazole (Eiken Chemical Co., Tokyo, Japan) and plates prepared in-house for posaconazole (Sigma-Aldrich, Brazil). Aspergillus flavus strain ATCC 204304, Candida parapsilosis strain ATCC 22019, and Candida krusei strain ATCC 6258 were included as quality controls in each test.

Detection of CYP51A mutations.DNA was extracted from 48-h fungal cultures as described above. Oligonucleotides used for amplification and sequence analysis of CYP51A were AF1P1 (F/R), AF2P1 (F/R), AF3P1 (F/R), and AF4P1 (F/R). Sequences were aligned with an azole-susceptible strain sequence (GenBank accession no. AF338659) using Geneious 8.1 (2015; Biomatters Ltd., Newark, NJ, USA) (12).

Microsatellite genotyping.For genotyping, PCR was performed using 9 pairs of primers and sequencing ≈400 bp from the isolates as described previously. Repeat numbers of each region (2A, 2B, 2C, 3A, 3B, 3C, 4A, 4B, and 4C) of the sequence were counted (16).

Ethical considerations.The present study was approved by the local Ethics Committee (CAAE51794615.0.0000.5404).

Accession number(s).CYP51A sequences were deposited in the NCBI database under GenBank accession numbers MN684333 (LIF 2444-6) and MN684334 (LIF 2552-4.9).

ACKNOWLEDGMENTS

L. Pontes and C. A. G. Beraquet received scholarships financed by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—Brasil (CAPES), finance code 001. This project was supported by grants from the collaborative research project Science and Technology Research Partnership for Sustainable Development (SATREPS), Japan, and the University of Campinas, Brazil, no. 02-P-9427/2018.

L.P and A.Z.S. conceived and designed experiments. C.A.G.B., T.A., G.L.P., and L.L. contributed to the acquisition, analysis, and/or interpretation of data. L.P., C.A.G.B., and A.Z.S. drafted the manuscript, and A.W. and M.L.M. revised it critically for important intellectual content.

FOOTNOTES

    • Received 20 October 2019.
    • Returned for modification 15 December 2019.
    • Accepted 20 December 2019.
    • Accepted manuscript posted online 23 December 2019.
  • Copyright © 2020 American Society for Microbiology.

All Rights Reserved.

REFERENCES

  1. 1.↵
    1. Perez-Cantero A,
    2. Lopez-Fernandez L,
    3. Guarro-Artigas J,
    4. Capilla J
    . 19 September 2019. Update and recent advances on azole resistance mechanisms in Aspergillus. Int J Antimicrob Agents doi:10.1016/j.ijantimicag.2019.09.011.
    OpenUrlCrossRef
  2. 2.↵
    1. Singh N,
    2. Paterson DL
    . 2005. Aspergillus infections in transplant recipients. Clin Microbiol Rev 18:44–69. doi:10.1128/CMR.18.1.44-69.2005.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Sun KS,
    2. Tsai CF,
    3. Chen SC,
    4. Huang WC
    . 2017. Clinical outcome and prognostic factors associated with invasive pulmonary aspergillosis: an 11-year follow-up report from Taiwan. PLoS One 12:e0186422. doi:10.1371/journal.pone.0186422.
    OpenUrlCrossRef
  4. 4.↵
    1. Rivero-Menendez O,
    2. Soto-Debran JC,
    3. Medina N,
    4. Lucio J,
    5. Mellado E,
    6. Alastruey-Izquierdo A
    . 2019. Molecular identification, antifungal susceptibility testing, and mechanisms of azole resistance in Aspergillus species received within a surveillance program on antifungal resistance in Spain. Antimicrob Agents Chemother 63:e00865-19.
  5. 5.↵
    1. Chowdhary A,
    2. Kathuria S,
    3. Randhawa HS,
    4. Gaur SN,
    5. Klaassen CH,
    6. Meis JF
    . 2012. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India. J Antimicrob Chemother 67:362–366. doi:10.1093/jac/dkr443.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Wiederhold NP,
    2. Gil VG,
    3. Gutierrez F,
    4. Lindner JR,
    5. Albataineh MT,
    6. McCarthy DI,
    7. Sanders C,
    8. Fan H,
    9. Fothergill AW,
    10. Sutton DA
    . 2016. First detection of TR34 L98H and TR46 Y121F T289A Cyp51 mutations in Aspergillus fumigatus isolates in the United States. J Clin Microbiol 54:168–171. doi:10.1128/JCM.02478-15.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. van der Linden JW,
    2. Arendrup MC,
    3. Warris A,
    4. Lagrou K,
    5. Pelloux H,
    6. Hauser PM,
    7. Chryssanthou E,
    8. Mellado E,
    9. Kidd SE,
    10. Tortorano AM,
    11. Dannaoui E,
    12. Gaustad P,
    13. Baddley JW,
    14. Uekotter A,
    15. Lass-Florl C,
    16. Klimko N,
    17. Moore CB,
    18. Denning DW,
    19. Pasqualotto AC,
    20. Kibbler C,
    21. Arikan-Akdagli S,
    22. Andes D,
    23. Meletiadis J,
    24. Naumiuk L,
    25. Nucci M,
    26. Melchers WJ,
    27. Verweij PE
    . 2015. Prospective multicenter international surveillance of azole resistance in Aspergillus fumigatus. Emerg Infect Dis 21:1041–1044. doi:10.3201/eid2106.140717.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Toyotome T,
    2. Hagiwara D,
    3. Kida H,
    4. Ogi T,
    5. Watanabe A,
    6. Wada T,
    7. Komatsu R,
    8. Kamei K
    . 2017. First clinical isolation report of azole-resistant Aspergillus fumigatus with TR34/L98H-type mutation in Japan. J Infect Chemother 23:579–581. doi:10.1016/j.jiac.2016.12.004.
    OpenUrlCrossRef
  9. 9.↵
    1. Alvarez-Moreno C,
    2. Lavergne RA,
    3. Hagen F,
    4. Morio F,
    5. Meis JF,
    6. Le Pape P
    . 2017. Azole-resistant Aspergillus fumigatus harboring TR34/L98H, TR46/Y121F/T289A and TR53 mutations related to flower fields in Colombia. Sci Rep 7:45631. doi:10.1038/srep45631.
    OpenUrlCrossRef
  10. 10.↵
    1. Isla G,
    2. Leonardelli F,
    3. Tiraboschi IN,
    4. Refojo N,
    5. Hevia A,
    6. Vivot W,
    7. Szusz W,
    8. Córdoba SB,
    9. García-Effron G
    . 2018. First clinical isolation of an azole-resistant Aspergillus fumigatus isolate harboring a TR46 Y121F T289A mutation in South America. Antimicrob Agents Chemother 62:e00872-18. doi:10.1128/AAC.00872-18.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Bustamante B,
    2. Illescas LR,
    3. Posadas A,
    4. Campos PE
    . 2020. Azole resistance among clinical isolates of Aspergillus fumigatus in Lima-Peru. Med Mycol 58:54–60. doi:10.1093/mmy/myz032.
    OpenUrlCrossRef
  12. 12.↵
    1. Reichert-Lima F,
    2. Lyra L,
    3. Pontes L,
    4. Moretti ML,
    5. Pham CD,
    6. Lockhart SR,
    7. Schreiber AZ
    . 2018. Surveillance for azoles resistance in Aspergillus spp. highlights a high number of amphotericin B-resistant isolates. Mycoses 61:360–365. doi:10.1111/myc.12759.
    OpenUrlCrossRef
  13. 13.↵
    1. Negri CE,
    2. Goncalves SS,
    3. Sousa ACP,
    4. Bergamasco MD,
    5. Martino MDV,
    6. Queiroz-Telles F,
    7. Aquino VR,
    8. Castro PTO,
    9. Hagen F,
    10. Meis JF,
    11. Colombo AL
    . 2017. Triazole resistance is still not emerging in Aspergillus fumigatus isolates causing invasive aspergillosis in Brazilian patients. Antimicrob Agents Chemother 61:e00608-17. doi:10.1128/AAC.00608-17.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Bedin Denardi L,
    2. Hoch Dalla-Lana B,
    3. Pantella Kunz de Jesus F,
    4. Bittencourt Severo C,
    5. Morais Santurio J,
    6. Zanette RA,
    7. Hartz Alves S
    . 2018. In vitro antifungal susceptibility of clinical and environmental isolates of Aspergillus fumigatus and Aspergillus flavus in Brazil. Braz J Infect Dis 22:30–36. doi:10.1016/j.bjid.2017.10.005.
    OpenUrlCrossRef
  15. 15.↵
    1. Denardi LB,
    2. Melchers WJG,
    3. Zoll J,
    4. Buil J,
    5. Hagen F,
    6. Meis JFG,
    7. Alves SH,
    8. Verweij PE
    . 2018. First report of azole-resistant Aspergillus fumigatus harboring TR34/L98H and M220R in Brazil, abstr S6.6c. 20th Congr Int Soc Human Anim Mycol (ISHAM 20th). https://www.aspergillus.org.uk/conference_abstracts/first-report-azole-resistant-aspergillus-fumigatus-harboring-tr34l98h-and-m220r.
  16. 16.↵
    1. Chen Y,
    2. Li Z,
    3. Han X,
    4. Tian S,
    5. Zhao J,
    6. Chen F,
    7. Su X,
    8. Zhao J,
    9. Zou Z,
    10. Gong Y,
    11. Qu F,
    12. Qiu G,
    13. Wang S,
    14. Jia X,
    15. Lu Z,
    16. Hu M,
    17. Huang L,
    18. Verweij PE,
    19. Han L
    . 2018. Elevated MIC values of imidazole drugs against Aspergillus fumigatus isolates with TR34/L98H/S297T/F495I mutation. Antimicrob Agents Chemother 62:e01549-17. doi:10.1128/AAC.01549-17.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Chen YC,
    2. Kuo SF,
    3. Wang HC,
    4. Wu CJ,
    5. Lin YS,
    6. Li WS,
    7. Lee CH
    . 2019. Azole resistance in Aspergillus species in Southern Taiwan: an epidemiological surveillance study. Mycoses 62:1174–1181. doi:10.1111/myc.13008.
    OpenUrlCrossRef
  18. 18.↵
    1. Reichert-Lima F
    . 2018. Avaliação de isolados clínicos e ambientais de Aspergillus spp.: caracterização morfológica e molecular de espécies, perfil de suscetibilidade e busca por mutações relacionadas à resistência aos antifúngicos azólicos. PhD thesis. Universidade Estadual de Campinas, Campinas, Brazil. http://repositorio.unicamp.br/jspui/bitstream/REPOSIP/332836/1/Lima_FranquelineReichert_D.pdf.
  19. 19.↵
    1. Alanio A,
    2. Cabaret O,
    3. Sitterlé E,
    4. Costa JM,
    5. Brisse S,
    6. Cordonnier C,
    7. Bretagne S
    . 2012. Azole preexposure affects the Aspergillus fumigatus population in patients. Antimicrob Agents Chemother 56:4948–4950. doi:10.1128/AAC.05990-11.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Hartung de Capriles C,
    2. Mata S,
    3. Middelveen M
    . 1989. Preservation of fungi in water (Castellani): 20 years. Mycopathologia 106:73–79. doi:10.1007/bf00437084.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Balajee SA,
    2. Houbraken J,
    3. Verweij PE,
    4. Hong SB,
    5. Yaghuchi T,
    6. Varga J,
    7. Samson RA
    . 2007. Aspergillus species identification in the clinical setting. Stud Mycol 59:39–46. doi:10.3114/sim.2007.59.05.
    OpenUrlCrossRefPubMed
  22. 22.↵
    Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. CLSI M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Aspergillus fumigatus Clinical Isolates Carrying CYP51A with TR34/L98H/S297T/F495I Substitutions Detected after Four-Year Retrospective Azole Resistance Screening in Brazil
Laís Pontes, Caio Augusto Gualtieri Beraquet, Teppei Arai, Guilherme Leite Pigolli, Luzia Lyra, Akira Watanabe, Maria Luiza Moretti, Angélica Zaninelli Schreiber
Antimicrobial Agents and Chemotherapy Feb 2020, 64 (3) e02059-19; DOI: 10.1128/AAC.02059-19

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Aspergillus fumigatus Clinical Isolates Carrying CYP51A with TR34/L98H/S297T/F495I Substitutions Detected after Four-Year Retrospective Azole Resistance Screening in Brazil
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Aspergillus fumigatus Clinical Isolates Carrying CYP51A with TR34/L98H/S297T/F495I Substitutions Detected after Four-Year Retrospective Azole Resistance Screening in Brazil
Laís Pontes, Caio Augusto Gualtieri Beraquet, Teppei Arai, Guilherme Leite Pigolli, Luzia Lyra, Akira Watanabe, Maria Luiza Moretti, Angélica Zaninelli Schreiber
Antimicrobial Agents and Chemotherapy Feb 2020, 64 (3) e02059-19; DOI: 10.1128/AAC.02059-19
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

azole resistance
Aspergillus fumigatus
drug resistance mechanisms

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596